|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a previous study, we have indicated that berberrubine (M3), a major metabolite of BBR in vivo, displays the most potential hypolipidemic effects via upregulating LDLR expression in human hepatoma (HepG2) cells compared with BBR and 3 other metabolites.
|
30335889 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, the role of low-density lipoprotein receptor (LDLR)-related protein 6 (LRP6) in HCC progression and the anti-HCC mechanism of SAMC was examined in clinical sample, cell model and xenograft/orthotopic mouse models.
|
30109182 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
|
27758865 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, RT-PCR, Western blotting and Oil Red O staining were used to investigate the effects of four BBR metabolites on LDLR expression and lipid accumulation in human hepatoma Hep G2 cells.
|
24321576 |
2014 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated reduced expression of the LDL receptor in HCC cases with paraneoplastic hypercholesterolemia.
|
17784865 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We investigate the expression of a LDL receptor protein and gene abnormalities of a LDL receptor in HCC cells in cases with paraneoplastic hypercholesterolemia.
|
17784865 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To study the mechanism of regulation of LDL-receptor by saturated fat and cholesterol at the cellular level, where any secondary effects of long-term feeding in vivo are minimized we used the cultured hepatoma and colon carcinoma cells, HepG2 and Caco2.
|
7595067 |
1995 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
|
8389767 |
1993 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, the effects of NB-598 on 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and low-density-lipoprotein (LDL) receptor were examined using a human hepatoma cell line Hep G2.
|
1649182 |
1991 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Under these conditions, the 3-fold increase in rate of synthesis of LDLr in the hepatomas was closely matched by increases in the level of its mRNA.
|
1653247 |
1991 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To determine whether two of these processes, cholesterol biosynthesis and receptor-mediated uptake of low-density lipoprotein (LDL), are co-ordinately regulated in human liver, we employed a human hepatoma cell line (HepG2) and measured the accumulation of mRNA for LDL receptor, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and HMG-CoA synthase under a variety of conditions.
|
2569863 |
1989 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of low-density-lipoprotein-receptor mRNA by insulin in human hepatoma Hep G2 cells.
|
2471639 |
1989 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ApoB-100 is synthesized in the liver, is the major protein constituent of low density lipoprotein, and serves as the ligand for the LDL receptor. cis-acting DNA sequence elements required for hepatic specific apoB transcription were identified in hepatoma (HepG2) and epithelial carcinoma (HeLa) cell lines transfected with apoB/CAT (chloramphenicol acetyltransferase) hybrid constructions.
|
3165376 |
1988 |